FDA gives ap­proval to No­var­tis' man­u­fac­tur­ing site for Plu­vic­to

No­var­tis said Fri­day that the pro­duc­tion fa­cil­i­ty for its ra­di­oli­gand ther­a­py Plu­vic­to has got­ten the thumbs-up from the FDA, and it plans to be­gin sup­ply­ing the prostate can­cer treat­ment for com­mer­cial use in the US from the new fa­cil­i­ty in Mill­burn, NJ.

The Swiss phar­ma said in a re­lease that man­u­fac­tur­ing is slat­ed to start in the com­ing weeks with a grad­ual ramp-up in pro­duc­tion, and ca­pac­i­ty at the fa­cil­i­ty is al­so ex­pect­ed to in­crease through­out the sec­ond half of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER